Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor - Takeaways - MDSpire

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor

  • By

  • Naseema Gangat

  • Kebede H. Begna

  • Aref Al-Kali

  • William Hogan

  • Mark Litzow

  • Animesh Pardanani

  • Ayalew Tefferi

  • January 4, 2023

  • 0 min

Share

  • 1

    Ruxolitinib, fedratinib, and pacritinib are FDA-approved JAK2 inhibitors for myelofibrosis, while momelotinib's approval is pending.

  • 2

    Momelotinib demonstrated a 54% anemia response and 40% splenomegaly reduction in myelofibrosis patients, outperforming ruxolitinib in anemia management.

  • 3

    The study included 183 JAKi naïve myelofibrosis patients, with median follow-up of 3.7 years, revealing significant treatment discontinuation rates.

  • 4

    Patients on momelotinib had longer treatment durations compared to those on ruxolitinib, with 3-year discontinuation rates at 92% for all patients.

  • 5

    Clinical and molecular predictors of response and survival were analyzed, highlighting the need for further investigation into treatment impacts.

Original Source(s)

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor

  • by Naseema Gangat, Kebede H. Begna, Aref Al-Kali, William Hogan, Mark Litzow, Animesh Pardanani, Ayalew Tefferi

  • January 4, 2023

Related Content

Crossing the line: blood transfusion thresholds in ECMO

Multimodal management of late-stage Bockenheimer disease complicated by severe anemia and coagulopathy: a case report

Tocilizumab as a novel bridging therapy for surgery in dedifferentiated liposarcoma complicated by paraneoplastic leukemoid reaction, severe anemia, and thrombocytopenia: a case report